Clinical benefit of low molecular weight heparin for ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with glycoprotein IIb/IIIa inhibitor

Journal of Korean Medical Science

Volumn 25, Issue 11, 2010, Pages 1601-1608

  Cho, Jung Sun ^a   Her, Sung Ho ^a   Baek, Ju Yeal ^a   Park, Mahn Won ^a   Kim, Hyoung Doo ^a   Jeong, Myung Ho ^b   Ahn, Young Keun ^b   Chae, Shung Chull ^c   Hur, Seung Ho ^d   Hong, Taek Jong ^e   Kim, Young Jo ^f   Seong, In Whan ^g   Chae, Jei Keon ^h   Rhew, Jay Young ⁱ   Chae, In Ho ^j   Cho, Myeong Chan ^k   Bae, Jang Ho ^l   Rha, Seung Woon ^m   Kim, Chong Jim ⁿ   Choi, Donghoon ^o   Jang, Yang Soo ^o   Yoon, Junghan ^p   Chung, Wook Sung ^a   Cho, Jeong Gwan ^b   Seung, Ki Bae ^a   Park, Seung Jung ^q   more..

^a The Catholic University of Korea   (South Korea)

^b Chonnam National University Medical School   (South Korea)

^c Kyungpook National University   (South Korea)

^d Dongsan Medical Center   (South Korea)

^e Pusan National University School of Medicine   (South Korea)

^f Yeungnam University   (South Korea)

^g Chungnam National University   (South Korea)

^h Chonbuk National University Medical School   (South Korea)

ⁱ Jeonju Presbyterian Medical Center   (South Korea)

^j Seoul National University Bundang Hospital   (South Korea)

^k Chungbuk National University   (South Korea)

^l Konyang University   (South Korea)

^m Korea University College of Medicine   (South Korea)

ⁿ Kyung Hee University College of Medicine   (South Korea)

^o Yonsei University   (South Korea)

^p Wonju Severance Christian Hospital   (South Korea)

^q Asan Medical Center   (South Korea)

more..

Author keywords

Blood platelets; Heparin; Myocardial infarction; Prognosis

Indexed keywords

FIBRINOGEN RECEPTOR; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ACUTE DISEASE; AGED; ARTICLE; BLEEDING; DRUG ANTAGONISM; DRUG COMBINATION; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MALE; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PROGNOSIS; REGISTER; RISK;

ACUTE DISEASE; AGED; DRUG THERAPY, COMBINATION; FEMALE; HEMORRHAGE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; ODDS RATIO; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROGNOSIS; REGISTRIES;

EID: 78449303538     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2010.25.11.1601     Document Type: Article

References (27)

1. Collet JP, Montalescot G, Agnelli G, Van de Werf F, Gurfinkel EP, López-Sendón J, Laufenberg CV, Klutman M, Gowda N, Gulba D; GRACE Investigators. Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events. Eur Heart J 2005; 26: 2285-93.
2. Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, Kereiakes DJ, Langer A, Mahaffey KW, Nessel CC, Armstrong PW, Avezum A, Aylward P, Becker RC, Biasucci L, Borzak S, Col J, Frey MJ, Fry E, Gulba DC, Guneri S, Gurfinkel E, Harrington R, Hochman JS, Kleiman NS, Leon MB, Lopez-Sendon JL, Pepine CJ, Ruzyllo W, Steinhubl SR, Teirstein PS, Toro-Figueroa L, White H; SYNERGY Trial Investigators. Enoxaparin vs. unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004; 292: 45-54.
3. White HD, Kleiman NS, Mahaffey KW, Lokhnygina Y, Pieper KS, Chiswell K, Cohen M, Harrington RA, Chew DP, Petersen JL, Berdan LG, Aylward PE, Nessel CC, Ferguson JJ 3rd, Califf RM. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. Am Heart J 2006; 152: 1042-50.
4. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomized trial in acute myocardial infarction. Lancet 2001; 358: 605-13.
5. Wallentin L, Goldstein P, Armstrong PW, Granger CB, Adgey AA, Arntz HR, Bogaerts K, Danays T, Lindahl B, Mäkijärvi M, Verheugt F, Van de Werf F. Efficacy and safety of tenecteplase in combination with the lowmolecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation 2003; 108: 135-42.
6. Antman EM, Morrow DA, McCabe CH, Murphy SA, Ruda M, Sadowski Z, Budaj A, López-Sendón JL, Guneri S, Jiang F, White HD, Fox KA, Braunwald E; ExTRACT-TIMI 25 Investigators. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 2006; 354: 1477-88.
7. Montalescot G, White HD, Gallo R, Cohen M, Steg PG, Aylward PE, Bode C, Chiariello M, King SB 3rd, Harrington RA, Desmet WJ, Macaya C, Steinhubl SR; STEEPLE Investigators. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 2006; 355: 1006-17.
8. Montalescot G, Ellis SG, de Belder MA, Janssens L, Katz O, Pluta W, Ecollan P, Tendera M, van Boven AJ, Widimsky P, Andersen HR, Betriu A, Armstrong P, Brodie BR, Herrmann HC, Neumann FJ, Effron MB, Lu J, Barnathan ES, Topol EJ; Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events Investigators. Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events). JACC Cardiovasc Interv 2010; 3: 203-12.
9. Klinkhardt U, Graff J, Westrup D, Kirchmaier CM, Esslinger HU, Breddin HK, Harder S. Pharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects. Br J Clin Pharmacol 2001; 52: 297-305.
10. Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low molecular-weight heparin and with a direct thrombin inhibitor. Circulation 1998; 97: 251-6.
11. Westwick J, Scully MF, Poll C, Kakkar W. Comparison of low molecular weight heparin and unfractionated heparin on activation of human platelets in vitro. Thromb Res 1986; 42: 435-47.
12. Deliargyris EN, Upadhya B, Melton LG, Thompson C, Fisher M, Gabriel DA, Dehmer GJ, Sane DC. Unfractionated heparin reduces the antiplatelet effects of abciximab but not eptifibatide during PCI. Clin Appl Thromb Hemost 2006; 12: 458-64.
13. Lee SR, Jeong MH, Ahn YK, Chae SC, Hur SH, Kim YJ, Seong IW, Chae JK, Hong TJ, Rhew JY, Cho MC, Bae JH, Rha SW, Kim CJ, Jang YS, Park SJ; Korea Acute Myocardial Infarction Registry Investigators. Clinical safety of drug-eluting stents in the Korea Acute Myocardial Infarction Registry. Circ J 2008; 72: 392-8.
14. Lee SH, Park JS, Kim W, Shin DG, Kim YJ, Kim DS, Choi DJ, Han KR, Kim CJ, Cho MC, Chae SC, Jeong MH; Korean Acute Myocardial Infarction Registry Investigators. Impact of body mass index and waist-to-hip ratio on clinical outcomes in patients with ST-segment elevation acute myocardial infarction (from the Korean Acute Myocardial Infarction Registry). Am J Cardiol 2008; 102: 957-65.
15. Song YB, Hahn JY, Gwon HC, Kim JH, Lee SH, Jeong MH; KAMIR investigators. The impact of initial treatment delay using primary angioplasty on mortality among patients with acute myocardial infarction: from the Korea Acute Myocardial Infarction Registry. J Korean Med Sci 2008; 23: 357-64.
16. Lee JH, Park HS, Chae SC, Cho Y, Yang DH, Jeong MH, Kim YJ, Kim KS, Hur SH, Seong IW, Hong TJ, Cho MC, Kim CJ, Jun JE, Park WH; Korea Acute Myocardial Infarction Registry Investigators. Predictors of sixmonth major adverse cardiac events in 30-day survivors after acute myocardial infarction (from the Korea Acute Myocardial Infarction Registry). Am J Cardiol 2009; 104: 182-9.
17. Kwon TG, Bae JH, Jeong MH, Kim YJ, Hur SH, Seong IW, Cho MC, Seung KB, Jang YS, Park SJ; Korea Acute Myocardial Infarction Registry Investigators. N-terminal pro-B-type natriuretic peptide is associated with adverse short-term clinical outcomes in patients with acute ST-elevation myocardial infarction underwent primary percutaneous coronary intervention. Int J Cardiol 2009; 133: 173-8.
18. Li YJ, Rha SW, Chen KY, Poddar KL, Jin Z, Minami Y, Wang L, Dang Q, Li GP, Ramasamy S, Park JY, Choi CU, Kim JW, Kim EJ, Park CG, Seo HS, Oh DJ, Jeong MH, Ahn YK, Hong TJ, Park JS, Kim YJ, Hur SH, Seong IW, Chae JK, Cho MC, Bae JH, Choi DH, Jang YS, Chae IH, Kim HS, Kim CJ, Yoon JH, Ahn TH, Tahk SJ, Chung WS, Seung KB, Park SJ; other Korea Acute Myocardial infarction Registry Investigators. Low-molecular-weight heparin versus unfractionated heparin in acute ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with drug-eluting stents. Am Heart J 2010; 159: 684-90.
19. Thomson C, Forbes CD, Prentice CR. The potentiation of platelet aggregation and adhesion by heparin in vitro and in vivo. Clin Sci Mol Med 1973; 45: 485-94.
20. Eika C. On the mechanism of platelet aggregation induced by heparin, protamine and polybrene. Scand J Haematol 1972; 9: 248-57.
21. Steinhubl SR, Talley JD, Braden GA, Tcheng JE, Casterella PJ, Moliterno DJ, Navetta FI, Berger PB, Popma JJ, Dangas G, Gallo R, Sane DC, Saucedo JF, Jia G, Lincoff AM, Theroux P, Holmes DR, Teirstein PS, Kereiakes DJ. Point-of-Care measured platelet inhibition correlates with a reduced risk of an adverse cardiac even after percutaneous coronary intervention. Results of the GOLD (AU-assessing Ultegra) Multicenter Study. Circulation 2001; 103: 2572-8.
22. The IMPACT II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 1997; 349: 1422-8.
23. Ruff CT, Wiviott SD, Morrow DA, Mohanavelu S, Murphy SA, Antman EM, Braunwald E; ExTRACT-TIMI 25 Investigators. TIMI risk index and the benefit of enoxaparin in patients with ST-elevation myocardial in farction. Am J Med 2007; 120: 993-8.
24. Murphy SA, Gibson CM, Morrow DA, Van de Werf F, Menown IB, Goodman SG, Mahaffey KW, Cohen M, McCabe CH, Antman EM, Braunwald E. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. Eur Heart J 2007; 28: 2077-86.
25. Montalescot G, Collet JP, Lison L, Choussat R, Ankri A, Vicaut E, Perlemuter K, Philippe F, Drobinski G, Thomas D. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. J Am Coll Cardiol 2000; 36: 110-4.
26. Simoons ML; GUSTO IV-ACS Investigators. Effect of glycoprotein Ilb/Illa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularization: the GUSTO IV-ACS randomised trial. Lancet 2001; 357: 1915-24.
27. Burgess JK, Chong BH. The platelet proaggregating and potentiating effects of unfractionated heparin, low molecular weight heparin and heparinoid in intensive care patients and health controls. Eur J Haematol 1997; 58: 279-85.